Skip NavigationSkip to Content
Return Return to Search Results

Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses

  1. Author:
    Hicks, Jennifer
    Klumpp-Thomas, Carleen
    Kalish, Heather
    Shunmugavel, Anandakumar
    Mehalko, Jennifer
    Denson, John-Paul
    Snead, Kelly R.
    Drew, Matthew
    Corbett, Kizzmekia S.
    Graham, Barney S.
    Hall, Matthew D.
    Memoli, Matthew J.
    Esposito, Dominic
    Sadtler, Kaitlyn

  2. Author Address

    Natl Inst Biomed Imaging & Bioengn, Trans NIH Shared Resource Biomed Engn & Phys Sci, NIH, Bethesda, MD 20894 USA.Natl Inst Biomed Imaging & Bioengn, Sect Immunoengn, NIH, Bethesda, MD 20892 USA.NIH, Natl Ctr Adv Translat Sci, Rockville, MD 20850 USA.Frederick Natl Lab Canc Res, Canc Res Technol Program, Prot Express Lab, NCI RAS Initiat, Frederick, MD 21702 USA.NIAID, Vaccine Res Ctr, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.NIAID, LID Clin Studies Unit, Lab Infect Dis, Div Intramural Res,NIH, Bethesda, MD 20894 USA.
    1. Year: 2021
    2. Date: Jul
    3. Epub Date: 2021 Mar 16
  2. Journal: Journal of Clinical Immunology
  3. Springer/Plenum Publishers
    1. 41
    2. 5
    3. Pages: 906-913
  5. Type of Article: Article
  6. ISSN: 0271-9142
  1. Abstract:

    In order to properly understand the spread of SARS-CoV-2 infection and development of humoral immunity, researchers have evaluated the presence of serum antibodies of people worldwide experiencing the pandemic. These studies rely on the use of recombinant proteins from the viral genome in order to identify serum antibodies that recognize SARS-CoV-2 epitopes. Here, we discuss the cross-reactivity potential of SARS-CoV-2 antibodies with the full spike proteins of four other betacoronaviruses that cause disease in humans, MERS-CoV, SARS-CoV, HCoV-OC43, and HCoV-HKU1. Using enzyme-linked immunosorbent assays (ELISAs), we detected the potential cross-reactivity of antibodies against SARS-CoV-2 towards the four other coronaviruses, with the strongest cross-recognition between SARS-CoV-2 and SARS /MERS-CoV antibodies, as expected based on sequence homology of their respective spike proteins. Further analysis of cross-reactivity could provide informative data that could lead to intelligently designed pan-coronavirus therapeutics or vaccines.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1007/s10875-021-00997-6
  3. PMID: 33725211
  4. PMCID: PMC7962425
  5. View record in Web of Science®
  6. WOS: 000629468300001

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel